score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	MET	Amplification				0.0	0.0		Putatively Actionable	Crizotinib	MET inhibition	Targeted therapy	Crizotinib is an available targeted agent with activity against MET amplifications in metastatic, NSCLC.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf	Putatively Actionable	Gefitinib	EGFR inhibition	Targeted therapy	Amplification of alternative kinases, such as MET, may suggest resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf						0				MET Amplification	0.0	KIRP-AL-3468	TCGA-AL-3468-01	
Putatively Actionable		Clinical evidence		Copy Number	BRAF	Amplification				0.0	0.0									Putatively Actionable	Vemurafenib	B-RAF inhibition	Targeted therapy	Amplification of BRAF may predict resistance to RAF inhibition.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631						0				BRAF Amplification		KIRP-AL-3468	TCGA-AL-3468-01	
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 5	version 2	0.308						Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	COSMIC Signature 5 is associated with somatic ERCC2 mutations, which may suggest sensitivity to cisplatin based chemotherapy.	Kim J, Mouw KW, Polak P, et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016;48(6):600-606.	https://doi.org/10.1038/ng.3557													0				COSMIC Signature (version 2) 5 (31%)		KIRP-AL-3468		
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.S704R	0.5965	57.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0	5.0	0.8	0.33399999999999996	BARD1 p.S704R (Missense)	0.0	KIRP-AL-3468	KIRP-AL-3468-TP	KIRP-AL-3468-NB
Biologically Relevant				Copy Number	PMS2	Amplification				0.0	0.0																					0				PMS2 Amplification		KIRP-AL-3468	TCGA-AL-3468-01	
Biologically Relevant				Copy Number	POT1	Amplification				0.0	0.0																					0				POT1 Amplification		KIRP-AL-3468	TCGA-AL-3468-01	
Biologically Relevant				Copy Number	EZH2	Amplification				0.0	0.0																					0				EZH2 Amplification		KIRP-AL-3468	TCGA-AL-3468-01	
Biologically Relevant				Microsatellite Stability	Supporting variants		PMS2 Amplification, PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PMS2 Amplification, PRDM2 p.703_704insP (Insertion)		KIRP-AL-3468		
